Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103 Miller, K., O'Neill, A. M., Dang, C. T., Northfelt, D. W., Gradishar, W., Goldstein, L. J., Mayer, I. A., Brufsky, A., Bloom, S., Sparano, J. A., Tevaarwerk, A., Fox, K. R., Hendricks, C., Balcueva, E. P., Sledge, G. W. AMER SOC CLINICAL ONCOLOGY. 2014
View details for DOI 10.1200/jco.2014.32.15_suppl.500
View details for Web of Science ID 000358613202275